| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Laprituximab
CAS:1622327-38-1
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Laprituximab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Laprituximab (DHB86912)
CAS:1622327-38-1
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Laprituximab Basic information |
| Product Name: | Laprituximab | | Synonyms: | Laprituximab;Research Grade Laprituximab (DHB86912);Research Grade Laprituximab | | CAS: | 1622327-38-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Laprituximab Structure]() |
| | Laprituximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Laprituximab Usage And Synthesis |
| Uses | Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289[1]. | | in vivo | In the H292 xenograft tumor model, the minimally effective doses of Laprituximab (J2898A) is 3 mg/kg[1]. | | References | [1] Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8_Supplement): 5467-5467. |
| | Laprituximab Preparation Products And Raw materials |
|